sightLEUKEMIA VACCINE•3d
0
votes
2
seen

Sellas’s galinpepimut-S extends survival to 24 months in relapsed AML

Sellas’s leukemia treatment extended median overall survival to 24.0 months, versus 14.7 months with physician-selected standard care. The Phase 3 REGAL trial enrolled 126 adults with relapsed acute myeloid leukemia who had returned to remission and were not transplant candidates.

Galinpepimut-S is a maintenance immunotherapy aimed at WT1, a protein overproduced by many leukemia cells. Sellas reported a hazard ratio of 0.59 and p=0.035 after 80 prespecified deaths, but the study was small, open-label, unblinded, and not peer-reviewed; the company plans to seek FDA approval.

Timeline2
3d

Reports highlighted Sellas’s Phase 3 REGAL survival result for galinpepimut-S in relapsed acute myeloid leukemia.

3d

Further reporting detailed the 24.0-month versus 14.7-month median overall survival result in 126 adults.

1 comment
3d
Discussion

1 comment

Sign in to join the discussion